State action on biosimilar competition 'might be on horizon,' Ohio enforcer says
A senior Ohio antitrust enforcer signaled potential antitrust enforcement action from US state attorneys general to lower the cost of prescription drugs, specifically those in the biosimilar space.A senior Ohio antitrust...To view the full article, register now.
Already a subscriber? Click here to view full article